Telormedix taps Holldack as new CEO

Switzerland's Telormedix has appointed Dr. Johanna Holldack as its new chief executive officer. Release

London-based Lightlake Therapeutics has appointed Dr. Roger Crystal as CEO. Release

Jiangbo Pharmaceuticals announced the resignation of Haibo Xu, the company's chief operating officer. Release

Genetic test maker Sequenom has plugged another hole in its top ranks with the addition of Paul V. Maier as interim chief financial officer. Story

Questcor Pharmaceuticals announced that David Young, Pharm.D., Ph.D., currently a member of Questcor's board of directors, has been appointed to the newly created position of chief scientific officer, and Sian E. Bigora, Pharm.D. has been appointed to the newly created position of vice president regulatory affairs. Release

Advaxis has announced the appointment of Christopher Duignan to the role of senior vice president, finance. Release

China-Biotics said that Chief Financial Officer Lewis Fan resigned to pursue other interests. Story

Santaris Pharma A/S has expanded its executive team with the appointment of Mark Wedel, MD, FACP as vice president and chief medical officer and Stuart Mackey, JD as vice president strategy and chief business officer. Release

Medivation has named Hank Mansbach, M.D., as vice president of medical affairs. Release

WuXi PharmaTech Cayman named Hui Cai as its new vice president of business development. Release

Synteract has hired a new vice president of global project management, Rod M. Saponjic, Ph.D., MBA, and promoted others in the organization. Stewart Bieler has been promoted to chief operating officer, Ali Sadighian has become vice president of business development, and Kristi Clark has become managing director of the new Synteract office in Prague. Release

Organovo has appointed Robert Baltera, M.S., M.B.A, to its board of directors. Release

Sorrento Therapeutics announced that Martina Molsbergen has joined the company as vice president, business development. Release

Inovio Biomedical has elected David J. Williams and Keith H. Wells as directors. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.